LUTETIUM-177 PSMA RADIOLIGAND THERAPY PROGRAM WITH PSMA PET SCAN
What's included in this package
Medical Procedures
- Lutetium-177 therapy
- Complete blood count (CBC)
Duration
Accommodation
Accommodation is not included
Transport
Transfer airport-clinic-airport
Additional information
The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer.
This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway.
Before therapy, a specialized PSMA PET/CT scan is performed and evaluated at our hospital to assess PSMA receptor expression and determine the extent of disease. Treatment eligibility and the final therapy decision are based on this comprehensive molecular imaging assessment, ensuring that only suitable patients proceed to Lutetium-177 PSMA therapy.
The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled cancer cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile.
The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols.
The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance.
The treatment package includes nuclear medicine consultation, comprehensive laboratory testing to assess kidney, liver, and hematologic function, administration of Lutetium-177 PSMA therapy, and structured post-treatment follow-up by a nuclear medicine specialist.
The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.
For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.
24/7 Bookimed assistance
- Personal medical coordinator
- Medical travel arrangements — booking of air tickets and hotel rooms at special partner prices
- Patient advocacy during medical travel
Program price
What's NOT included in this package
Doctor
How are we doing?
About the clinic
Lutetium-177 therapy is a targeted radionuclide treatment for prostate cancer available at Anadolu Medical Center in Gebze, Turkey. One cycle may cost around $10,000 USD, with the clinic offering Johns Hopkins-affiliated care and JCI accreditation. The treatment is overseen by nuclear medicine specialist Assoc. Prof. Dr. Kezban Berberoğlu, who specializes in PSMA therapy evaluation.
Treatment Details
Lu-177 PSMA therapy delivers radiation directly to prostate cancer cells. It uses intravenous administration of Lu-177-PSMA-617. Most patients receive treatment as outpatients with optional 1-day hospitalization.
What's Included
- Lu-177 radioactive medication
- Treatment materials and consumables
- Nuclear medicine examination
- Post-treatment scan and evaluation
Preparation and Recovery
Patients need recent PSMA PET-CT scans and kidney function tests before treatment. The total stay in Turkey typically lasts 3-5 days. Most patients can fly home within 48 hours after therapy. Mild fatigue may occur for 1-3 days post-treatment.
Additional Services
The clinic provides free airport transfers and medical interpreters. Patients receive radiation safety guidance for 7 days after therapy. Flight clearance is given 2 days post-treatment.
This advanced therapy offers precise cancer targeting with specialized oversight. Contact the clinic to discuss your eligibility and treatment plan.
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.